Sort by 'likes'
Nonsecretory Multiple Myeloma: New Options in Assessment and Treatment
Hallmark of most multiple myeloma cases is the persistent production of some form of immunoglobulins, a phenomenon that brings the disease to attention. However, there is a subset of multiple myeloma patients who do not secrete immunoglobulin or its component…
Using Clinical Data to Determine Treatments in Myeloma
Using Clinical Trial Data to Determine Treatment Options, has been successfully implemented by Dr. McCarthy and team and here he discusses the various preclinical new drug developments for myeloma treatment
Osteonecrosis of the Jaw & Myeloma with Dr. John Killip – On-Air Myeloma Support Group
Osteonecrosis of the Jaw (ONJ) is a condition associated with a loss of blood supply to the jaw, causing the jawbone tissue death. Although the prevalence of ONJ is below 1%, it is more common in multiple myeloma patients as…
Latest developments in multiple myeloma with Dr. Ravi Vij
In the first episode of the Multiple Myeloma Curetalk with Dr. Ravi Vij of Washington University, St. Louis, we discuss the latest developments in Multiple Myeloma.
Myeloma with The MMRF
Towards the end of last year in 2013, MMRF rolled out three important cancer research initiatives - big data and genomic sequencing, open access by sharing research data, and empowering patients to find clinical trials that are best for them…